Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.
You may also be interested in...
Merck Builds On Januvia Momentum With Two Supplementary Claims
Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.
Merck Builds On Januvia Momentum With Two Supplementary Claims
Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.
Merck Janumet Study Demonstrates Glucose Reductions In Two Measures
Data on the investigational type 2 diabetes drug is pivotal to Merck’s NDA submission for the sitagliptin/metformin combination.